No Data
No Data
No Data
No Data
No Data
Purple Biotech Advances in Oncology Drug Development
TipRanksMay 3 04:58
HC Wainwright & Co. : The Purple Biotech (PPBT.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
HC Wainwright & Co. : The Purple Biotech (PPBT.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
Zhitong FinanceApr 27 02:30
Buy Rating Affirmed on Purple Biotech's CM24 Favorable Interim Phase 2 Results in PDAC Treatment
Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Purple Biotech (PPBT – Research Report). The associated price target remains the same with $10.00.
TipRanksApr 27 00:15
Purple Biotech's Cancer Study Shows Promise
Purple Biotech Ltd. (PPBT) has released an update.
TipRanksApr 25 19:57
Purple Biotech Says Randomized Phase 2 CM24 Pancreatic Cancer Study Selected As Late-Breaking Abstract Poster Presentation At ASCO 2024 Annual Meeting
Purple Biotech Says Randomized Phase 2 CM24 Pancreatic Cancer Study Selected As Late-Breaking Abstract Poster Presentation At ASCO 2024 Annual Meeting
BenzingaApr 25 19:25
12 Health Care Stocks Moving In Monday's After-Market Session
GainersNuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. The company's market cap stands at $3.2 million. Sensei Biotherapeutics (NASDAQ:SNSE) stock rose 7.42% to
BenzingaApr 23 04:31
No Data
No Data